11% CAGR growth by 2023 in the Brain Tumor Therapeutics Market| Dominant Players - F. HOFFMAN LA-ROCHE LTD., MERCK, NOVARTIS, NOVOCURE, DELMAR PHARMACEUTICALS INC., MOLECULIN BIOTECH, amongst others

Market Analysis:

North America to Dominate the Market
North America dominates the market due to the increasing technological advancements and the rising incidence of brain cancer in the country. Asia-Pacific is also expected to propel the market owing to factors, such as increasing accessibility to healthcare facilities in the region, and increasing geriatric population.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/16737
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

Increasing incidence of Brain Cancer has resulted in upsurge the demand for brain cancer across the globe which is driving the market. In addition, developed healthcare infrastructure, greater per capita healthcare spending, and comparatively higher awareness regarding advanced technologies, increased focus on precision medicine is also fuelling the global brain tumor therapeutics market. Few brain cancer specific drugs and their high cost is acting as a restraint for Brain Tumor therapeutics market. Although various pharmaceutical companies are spending heavily on R&D activities which can bring more treatment options to the market in future.

Request Discount on this report @ https://marketprognosis.com/discount-request/16737
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

Market Segments:
Brain Tumor Therapeutics Market is segmented by:
1. PRODUCT: CELL-BASED PRODUCTS, ACELLULAR PRODUCTS
2. THERAPY: CELL THERAPY, TISSUE ENGINEERING, IMMUNOTHERAPY, GENE THERAPY
3. APPLICATION: ORTHOPEDIC & MUSCULOSKELETAL DISORDERS, DERMATOLOGY, CARDIOLOGY, CENTRAL NERVOUS SYSTEM DISEASES, ONCOLOGY, DIABETES, OTHERS
4. GEOGRAPHY: NORTH AMERICA, SOUTH AMERICA, EUROPE, ASIA-PACIFIC, MIDDLE EAST AND AFRICA, SOUTH AMERICA

Key developments in the market
• In January, 2018 iTeos Therapeutics has regained rights to its Phase 1 brain cancer drug from Pfizer, and plans to continue oncology development.
• In December, 2017, Diffusion Pharmaceuticals (DFFN) Launches Phase 3 Trial for Glioblastoma

Enquiry before Buying @ https://marketprognosis.com/enquiry/16737
Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.”

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today's complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMark Pvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.